124 related articles for article (PubMed ID: 28462836)
1. Iodine catalyzed three component synthesis of 1-((2-hydroxy naphthalen-1-yl)(phenyl)(methyl))pyrrolidin-2-one derivatives: Rationale as potent PI3K inhibitors and anticancer agents.
Muralidharan VP; Alagumuthu M; Iyer SK
Bioorg Med Chem Lett; 2017 Jun; 27(11):2510-2514. PubMed ID: 28462836
[TBL] [Abstract][Full Text] [Related]
2. Molecular explorations of substituted 2-(4-phenylquinolin-2-yl) phenols as phosphoinositide 3-kinase inhibitors and anticancer agents.
Alagumuthu M; Arumugam S
Cancer Chemother Pharmacol; 2017 Feb; 79(2):389-397. PubMed ID: 28054203
[TBL] [Abstract][Full Text] [Related]
3. N-substituted hydroxynaphthalene imino-oxindole derivatives as new class of PI3-kinase inhibitor and breast cancer drug: Molecular validation and structure-activity relationship studies.
Rajesh Kumar M; Alagumuthu M; Violet Dhayabaran V
Chem Biol Drug Des; 2018 Jan; 91(1):277-284. PubMed ID: 28791774
[TBL] [Abstract][Full Text] [Related]
4. Efficient iodine catalyzed three components domino reaction for the synthesis of 1-((phenylthio)(phenyl)methyl)pyrrolidin-2-one derivatives possessing anticancer activities.
Ramachandran G; Karthikeyan NS; Giridharan P; Sathiyanarayanan KI
Org Biomol Chem; 2012 Jul; 10(28):5343-6. PubMed ID: 22695979
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylaminopyridin-5-yl)benzo[d]thiazol-2-yl)urea as anticancer agents with low toxicity.
Xie XX; Li H; Wang J; Mao S; Xin MH; Lu SM; Mei QB; Zhang SQ
Bioorg Med Chem; 2015 Oct; 23(19):6477-85. PubMed ID: 26321603
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and molecular docking studies of 2-(furan-2-yl)quinazolin-4-one derivatives as potential antiproliferative agents.
Ahmed MF; Belal A
Arch Pharm (Weinheim); 2015 Jul; 348(7):487-97. PubMed ID: 25921702
[TBL] [Abstract][Full Text] [Related]
7.
; ; . PubMed ID: 28254336
[No Abstract] [Full Text] [Related]
8.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
